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Various inhibitors of metallo--lactamases have been reported; however, none are effective for all subgroups.
Those that have been found to inhibit the enzymes of subclass B2 (catalytically active with one zinc) either
contain a thiol (and show less inhibition towards this subgroup than towards the dizinc members of B1 and
B3) or are inactivators behaving as substrates for the dizinc family members. The present work reveals that
certain pyridine carboxylates are competitive inhibitors of CphA, a subclass B2 enzyme. X-ray crystallographic
analyses demonstrate that pyridine-2,4-dicarboxylic acid chelates the zinc ion in a bidentate manner within the
active site. Salts of these compounds are already available and undergoing biomedical testing for various
nonrelated purposes. Pyridine carboxylates appear to be useful templates for the development of more-
complex, selective, nontoxic inhibitors of subclass B2 metallo--lactamases.
-Lactam antibiotics have long been used to fight bacterial
infections in medicine and agriculture. Bacteria have evolved
to hydrolyze -lactams, thus rendering them ineffective by the
production of -lactamases (16, 19, 31). Metallo--lactamases
(MBLs) constitute one of four classes of -lactamases, namely,
class B. However, unlike the other classes (A, C, and D), which
all contain a nucleophilic serine residue in their active site, the
MBLs utilize zinc to enable hydrolysis (1, 4, 6) of all the
-lactam antibiotics (with the exception of monobactams) (31).
There are three subclasses of MBLs, B1, B2, and B3, which
differ in their zinc dependency (17). Subclass B1 enzymes (such
as BcII of Bacillus cereus, IMP-1, VIM-2, and VIM-4) can
employ one or two zinc ions at their active site for full activity,
and subclass B3 enzymes (L1 enzyme produced by Stenotro-
phomonas maltophilia and FEZ-1 of Legionella gormanii) con-
tain two zinc ions (35, 36), but while subclass B2 enzymes (such
as CphA from Aeromonas hydrophila) are active with one zinc
ion, they are inhibited upon binding of a second zinc ion (22).
The heterogeneity of the -lactamases has proved problem-
atic in the search for a generic inhibitor. All the clinically used
inhibitors are effective only against the active-site serine -lac-
tamases as they are hydrolyzed by MBLs. Various inhibitors of
MBLs have been reported; in general, their side chains bind in
a predominantly hydrophobic pocket while their functional
groups interact with both zinc ions, e.g., in the case of thiol
inhibitors, the sulfur displaces the hydroxide ion that bridges
the two zinc ions (21, 34, 40). The search for inhibitors has
understandably focused on the plasmid-encoded IMP and
VIM variant MBLs (26, 29, 39). However, with respect to
subclass B2 enzymes, the reported inhibitors either have ex-
hibited a lower efficiency than that shown towards the other
subgroups (21, 34) or were products of substrate hydrolysis
acting as irreversible inactivators (44).
Subclass B2, which contains CphA from Aeromonas hy-
drophila, is characterized by a narrow specificity profile (lim-
ited to the efficient hydrolysis of carbapenems) and a noncom-
petitive inhibition by a second zinc ion binding to a low-affinity
site (22, 24). We are interested in identifying MBL inhibitor
templates that can be developed into broad-spectrum inhibi-
tors of the MBLs. Pyridine dicarboxylates are known to be
inhibitors of monometallic enzymes (25). Here, we reveal that
CphA is competitively inhibited by 2-picolinic acid and one of
its derivatives, pyridine-2,4-dicarboxylic acid (2,4-PDCA). The
crystal structure of the latter in complex with CphA-Zn(II) is
described. The activities of these inhibitors were also tested
against those of other enzymes, including the CphA N116H-
N220G mutant, an enzyme with a broader specificity than
wild-type CphA and without a significant loss of activity upon
binding of a second zinc, making it similar to subclass B1
enzymes (2).
MATERIALS AND METHODS
Chemicals. Buffers, bovine serum albumin (BSA), 2-picolinic acid, and its
derivatives were obtained from Sigma-Aldrich (Steinheim, Germany) or BDH
Chemicals (Poole, United Kingdom). Imipenem was obtained from Merck
Sharpe and Dohme Research Laboratories (Rahway, NJ), nitrocefin was ob-
tained from Unipath Oxoid (Basingstoke, United Kingdom), and cefotaxime was
obtained from Sigma (St. Louis, MO). Dimethyl sulfoxide (DMSO) and ZnCl2
were obtained from Merck (Darmstadt, Germany).
Enzyme preparation. IMP-1 (30), CphA (23), L1 (32, 42), FEZ-1 (33), and the
CphA N116H-N220G double mutant (2) were produced and purified as de-
scribed previously. BcII (35) was a kind gift from O. Jacquin (Universite´ de
Lie`ge) and the VIM enzymes (11) from P. Lassaux (Universite´ de Lie`ge).
Screening of inhibitors. Hydrolysis of nitrocefin (FEZ-1) or imipenem (all
other enzymes) was monitored by following the variation in absorbance at 300
nm or 482 nm, respectively, using a Uvikon 860 spectrophotometer connected to
a microcomputer via an RS232 serial interface. IMP-1, BcII, CphA, L1, and
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FEZ-1 enzymes were used at fixed concentrations between 0.03 and 0.7 nM. The
enzyme and inhibitor (100 M) were preincubated for 30 min at room temper-
ature before the substrate (100 M) was added. The activity was tested using the
initial rate of three samples and given as a mean percentage of the rate without
inhibitor present. The inhibitors were prepared as 10 mM stock solutions in
DMSO before dilution with 20 mM HEPES buffer, pH 7.0, containing 20 g/ml
BSA (and 100 M ZnCl2 where indicated). It was verified that the concentra-
tions of DMSO present had no inhibitory effects and that the rate remained the
same upon the addition of 1% DMSO.
Determination of the inhibition constant. More-detailed kinetics were per-
formed with 2-picolinic acid and 2,4-PDCA, which showed significant inhibition
for the CphA MBL. The buffer and enzyme concentrations were the same as
those used in the screening. Substrate concentrations varied between 20 and 200
M at three inhibitor concentrations and in the absence of inhibitor. Cells of
2-mm or 10-mm path length were used depending on the substrate concentra-
tion. Preincubation was found to be unnecessary, and the experiments were
performed at 30°C in thermostatically controlled cells. The initial rate conditions
were used to study the inhibition with imipenem by using the Hanes linearization of
the Henri-Michaelis equation and the KaleidaGraph 3.5 program. The competitive
inhibition constant, Ki, was then calculated using the following equation (9):
S
v

Km
V
1  I/Ki 
S
V
where [S] is substrate concentration, v is reaction rate, V is maximum velocity,
and [I] is inhibitor concentration. The Ki values were determined for the CphA
N116H-N220G double mutant with 2-picolinic acid and 2,4-PDCA under the
same conditions as those for the wild type. The Ki value was also determined for
the dizinc enzyme with cefotaxime as the substrate in 20 mM sodium cacodylate
buffer, pH 6.5, containing 20 g/ml BSA and 100 M ZnCl2, conditions under
which the enzyme is in the dizinc form (2). The enzyme dilution was performed
in the described buffer but without ZnCl2, since the enzyme is not stable for a
long period of time when Zn(II) is present.
pH study of the inhibition constant. The Ki values for picolinic acid and
2,4-PDCA with CphA were determined at different pH values from pH 7 to pH
10. Experiments were performed in a mixed buffer (containing 40 mM sodium
acetate, 20 mM sodium cacodylate, 20 mM MOPS [morpholinepropanesulfonic
acid], 20 mM TAPS {[2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]-1-propane-
sulfonic acid}, 20 mM CHES, [2-(cyclohexylamino)ethanesulfonic acid], 20 mM
CAPS [3-(cyclohexylamino)-1-propanesulfonic acid], and 20 g/ml BSA) ad-
justed with HCl or NaOH to the desired pH. Km and kcat for imipenem with
CphA were also determined under the same conditions.
Crystallization and data collection. Crystallization of the wild-type CphA was
performed as described previously (18). In brief, crystals were grown at 8°C using
the hanging drop method. The reservoir solution contained 30% (wt/vol) poly-
ethylene glycol 8000, 0.6 M ammonium sulfate, and 100 mM Na-citrate, pH 6.5.
The drops were obtained by mixing 2 l of protein solution (10 mg/ml) with an
equal volume of reservoir solution. The CphA–Zn(II)–2,4-PDCA complex was
obtained by adding an excess of 2,4-PDCA powder directly to a drop containing
CphA crystals.
Before data collection, crystals were transferred to a cryoprotectant solution
(reservoir solution containing 20% [vol/vol] glycerol) and then mounted rapidly
in loops and flash-cooled. X-ray data were collected in-house using a Nonius
FR591 rotating anode X-ray generator coupled to a Mar Research Imagine Plate
detector. Data were processed using CCP4 programs (Table 1) (7).
Structure determination and refinement. Initial phases for the CphA–Zn(II)–
2,4-PDCA complex structure were generated by molecular replacement, using
the structure of the wild-type CphA as a starting model (Protein Data Bank
accession code 1X8G). Refinement and model building were carried out using O
(27) and REFMAC (CCP4) (7). The calculation of the first (Fo 	 Fc) electron
density map clearly showed the presence of the inhibitor molecule in the active
site. 2,4-PDCA was modeled in the map after most of the protein main chain and
side chain atoms and most of the water molecules were built and refined.
Conformational torsion-angle restraints and charge assignments for the 2,4-
PDCA molecule were obtained using CCP4i Libcheck. Refinement statistics are
shown in Table 1.
Protein structure accession number. Coordinates and structure factors have
been deposited in the Protein Data Bank (3) with accession code 2GKL.
RESULTS AND DISCUSSION
Inhibitory activities of picolinic acid and its derivatives.
Since pyridine dicarboxylates are known inhibitors of mono-
metallic enzymes (25), they were investigated as MBL inhibi-
tors. Initially, 2-picolinic acid and five pyridine dicarboxylic
acid derivatives with 2,3, 2,4, 2,5 2,6, and 3,4 substitution pat-
terns (Fig. 1), each with two carboxylate groups at different
positions on the ring, were screened for inhibitory activity
against the subclass B1 enzymes IMP-1, BcII, VIM-2, and
VIM-4, the subclass B2 enzyme CphA, and the subclass B3
enzymes L1 and FEZ-1. The residual activities are shown in
FIG. 1. Structures of 2-picolinic acid and its derivatives, 2,3-PDCA,
2,4-PDCA, 2,5-PDCA, 2,6-PDCA (dipicolinic acid), and 3,4-PDCA,
which were tested as MBL inhibitors.
TABLE 1. Data collection and refinement statistics
Parameter Value for CphA–2,4-PDCAcomplexa
Data collection
Temperature (K) ........................................................100
Wavelength (Å)............................................................1.54179
Maximum resolution (Å) ...........................................1.86 (1.91–1.86)
No. of observed reflections ........................................260,971
No. of unique reflections............................................21,647
Space group.................................................................C2221
Unit cell (Å)
a .................................................................................42.6
b .................................................................................101.2
c .................................................................................117.1
Completeness (%).......................................................99.4 (99.4)
Multiplicity ...................................................................6.4 (6.0)
Rsym (%)
b......................................................................8 (39.5)
I/
(I) .............................................................................7.4 (4.1)
Refinement statistics
Rfactor/Rfree (%)
c ..........................................................15.7/19.0
Root mean square deviations
Bond length (Å) ......................................................0.013
Bond angle (°) .........................................................1.4
No. of atoms (non-H)
Protein ......................................................................1,770
Zn..............................................................................1
Pyridine-2,4-dicarboxylate ......................................12
Glycerol ....................................................................6  3d
Water ........................................................................194
Average B factor (Å2) ................................................14.2
a Numbers in parentheses are for the highest-resolution shell.
b Rsym  ¥khl  I (hkl) 	 I (hkl)/¥khl I (hkl).
c Rfactor  ¥khl  Fo (hkl) 	 Fc (hkl)/¥khl  Fo (hkl). Rfree was calculated based
on 5% of the total data omitted during structure refinement.
d Six molecules of glycerol per three CphA molecules.
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Table 2. When a residual activity is below 50%, the compound
is considered an inhibitor. Only inhibitors demonstrating such
values will produce Ki values low enough to be considered
significant.
2,6-PDCA (dipicolinic acid) is a known zinc chelator which
has been used in the identification (28) and characterization
(15, 30) of metalloenzymes, including the class B -lactamases.
The strong zinc chelation ability of 2,6-PDCA is consistent
with the large increase in activity seen upon the addition of
excess (100 M) ZnCl2 to the IMP-1 assay in the presence of
2,6-PDCA. It seems likely that in the absence of excess zinc,
2,6-PDCA chelates zinc so strongly that it depletes zinc from
the enzyme, thereby inactivating it. The large disparity be-
tween residual activities with and without added zinc as tested
on IMP-1 was not seen for any of the other pyridine dicarboxyl-
ates. In these cases, the position of the second carboxylic group
on the pyridine ring limits the ligand to less potent bidentate
metal chelation. However, the compounds are able to bind the
active-site zinc, causing enzyme inhibition if space and geom-
etry allow.
With the exception of the inhibition of CphA by 2,4-PDCA,
the dicarboxylic compounds showed little inhibitory activity
against any of the MBLs. CphA was slightly activated by the
presence of some compounds, possibly due to their ability to
chelate free zinc which inhibits the enzyme (22). 2-Picolinic
acid showed inhibitory activity against all the MBLs tested, to
various degrees. The activity was greatest for CphA; this may
reflect the relatively tight active site of this enzyme, as high-
lighted by crystallographic studies (18).
Further investigation of CphA inhibition by 2-picolinic acid
and the pyridine dicarboxylates by using the Hanes lineariza-
tion revealed that they act as competitive inhibitors (Fig. 2 and
Table 3). The Ki values indicate that 2,4-PDCA is the best
inhibitor and also the most specific for CphA. 2-Picolinic acid
did not show the same selectivity for subclass B2 but showed a
greater potency across the other MBLs tested (Table 2). The
least effective inhibitor with respect to CphA was 3,4-PDCA
(Table 3), which is the only compound tested that was unable
to use the nitrogen present to chelate the zinc bidentately.
pH study. The Ki values increased for both 2-picolinic acid
and 2,4-PDCA in the mixed buffer at pH 7 with respect to
those determined for sodium cacodylate at pH 7. This effect
was more pronounced for 2-picolinic acid, bearing one carbox-
ylate group, as its Ki value is increased approximately eightfold
when the buffer concentration is increased seven times whereas
2,4-PDCA shows a fourfold increase only. The differences in Ki
values may be due to a shielding effect on the electrostatic
interactions between Zn(II) and the inhibitors (5). The Ki
values for 2-picolinate and 2,4-PDCA were also determined at
FIG. 2. Hanes linearization for the inhibition of CphA by 2,4-
PDCA at 0, 10, and 20 M 2,4-PDCA, depicted by graphs of filled
circles, open diamonds, and open squares, respectively.
TABLE 2. Residual activities estimated as initial rates of substrate hydrolysis of MBLs after 30 min of preincubation
at room temperature with 2-picolinic acid and its derivativesa
Enzyme
Residual activity (%) in the presence of:
No inhibitor 2,3-PDCA 2,4-PDCA 2,5-PDCA 2,6-PDCA 3,4-PDCA 2-Picolinic acid
IMP-1 with no added Zn 100 89  2 94  4 99  4 2  4 91  5 31  8
IMP-1 100 67  3 78  3 81  2 72  2 88  7 54  6
BcII 100 98  4 97  3 99  2 95  3 97  3 95  5
VIM-2 100 106  6 98  5 97  3 96  8 92  3 80  2
VIM-4 100 73  3 90  1 97  2 88  2 100  1 59  2
CphA with no added Zn 100 130  10 38  4 114  14 12  17 116  3 8  18
L1 100 93  2 78  2 94  5 92  14 97  2 29  13
FEZ-1 100 62  4 65  6 80  11 77  6 93  8 62  2
a The reporter substrates used were nitrocefin (FEZ-1) and imipenem (all other enzymes) at a concentration of 100 M. Residual activity was tested in the presence
of 100 M inhibitor. Values are means  standard deviations.
TABLE 3. Competitive inhibition constant Ki of 2-picolinic acid
and its derivatives for CphA and the N116H-N220G
double mutanta
Inhibitor
Ki (M)
Wild type N116H-N220Gmutant
2,3-PDCA 200  20 ND
2,4-PDCA 4.5  0.5 28  4 (35  5)
2,5-PDCA 420  10 ND
3,4-PDCA 1,100  40 ND
2-Picolinic acid 5.7  0.9 13  2 (NA)
a Ki values were found using 100 M imipenem. Values are means  standard
deviations. The data shown in parentheses are those obtained with the dizinc
form. ND, not determined; NA, not applicable (see text).
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pH 8, pH 9, and pH 10. The results (Table 4) indicate that Ki
increases with increasing pH values, suggesting that as pH
increases the positive charge of the zinc ion is shielded by the
increasing number of hydroxide ions present (5), thus decreas-
ing the attraction of the inhibitor to the enzyme’s active site.
Unfortunately, it was not possible to obtain Ki values at pH 6
and below. When the enzyme was diluted in pH 6 buffer at 4°C,
the triplicate points showed that a significant decrease in ac-
tivity occurred for each subsequent point. This was tested over
a longer period of time and showed that the enzyme was
unstable at pH 6 (data not shown). To counter the problem of
instability, the enzyme was kept at pH 7 and added to the
reaction mix, which was at pH 6. However, the initial rate
produced was not linear at any time, so the activity was not
found. The relationship between pH and pKi (Fig. 3) seems to
be linear and interestingly affects 2,4-PDCA and 2-picolinic
acid to the same extent, as highlighted by the parallel nature of
the graphs.
Table 5 shows the Km and kcat values of CphA with imi-
penem in the pH range 7 to 10. The catalytic efficiency of the
enzyme (kcat/Km) decreased with increasing pH values across
the entire range. At pH 10, the stability of imipenem was such
that the rate of spontaneous hydrolysis was so high that the
individual kcat and Km values were unreliable and only the
value of kcat/Km was considered accurate. The decrease in
the catalytic efficiency is explained by the fact that the decrease
in kcat is more pronounced than the concomitant decrease in
Km. It is not known how the shielding effect discussed previ-
ously affects the constants that make up the Km value; hence,
it is able to decrease while the pH increases.
CphA N116H-N220G double mutant. Ki values for 2-picoli-
nate and 2,4-PDCA were also measured with the CphA
N116H-N220G double mutant (Table 3), which displays some
subgroup B1 characteristics, including the binding of two zinc
ions without the inhibition of catalysis. The N116H-N220G
mutant was inhibited by both 2-picolinic acid and 2,4-PDCA,
as was the wild type. However, the mutations, which broaden
the substrate profile of CphA, reversed the potency of the two
inhibitors so that the mutant behaved as B1 (and B3) enzymes,
which are more inhibited by 2-picolinic acid than by 2,4-PDCA.
The Ki values for the dizinc species of the N116H-N220G
mutant with 2,4-PDCA cannot be compared with those for the
monozinc species, as the experiments were performed under
different conditions. However, the result is interesting since it
suggests that 2,4-PDCA is specific for CphA rather than for a
monozinc enzyme. A different inhibitory profile was observed
for 2-picolinic acid. It was unable to inhibit the dizinc form of
the N116H-N220G mutant, showing no inhibition until the
inhibitor concentration was above the zinc concentration.
Above a concentration of 100 M, inhibition occurred with
2-picolinic acid but it was not competitive, as the Hanes lin-
earization graphs were not parallel (data not shown), suggest-
ing that a mix of mono- and dizinc forms were produced and
that the decrease in activity observed with the substrate cefo-
taxime was due to the decrease in activity which occurs upon
the removal of a zinc ion from the dizinc form. At similar zinc
concentrations, when imipenem was used as the substrate, an
increase in the rate of hydrolysis was seen. Again, this suggests
that the monozinc form is being produced since the hydrolysis
of imipenem is inhibited upon the binding of a second zinc
form (2).
2,4-PDCA–CphA complex structure. To investigate the
structural basis of the inhibition of CphA by 2,4-PDCA, crys-
tals of the inhibitor complexed to the CphA enzyme were
produced. The refined CphA–Zn(II)–2,4-PDCA complex
structure comprises 227 protein residues, 1 zinc ion, 1 2,4-
PDCA, 3 glycerols, and 194 water molecules (Table 1). The
protein structure of CphA in the complex is very close to that
of the wild-type protein (18), with a root mean square devia-
tion between the 227 C atoms of 0.15 Å. Superposition of the
two structures shows that the binding of the inhibitor leads to
the movement of the Gly232-Asn233 loop located at the active
site entrance so that it encloses the active site (Fig. 4).
The structure of the CphA–Zn(II)–2,4-PDCA complex
shows that the 2,4-PDCA inhibitor binds to the catalytic zinc
FIG. 3. pH dependence of the log10 of the competitive inhibition
constant Ki with 2,4-PDCA and 2-picolinic acid, depicted by graphs of
filled circles and open squares, respectively.
TABLE 4. pH dependence of the Ki values for 2,4-PDCA and
2-picolinic acid with CphA by using imipenem as the reporter
substrate at a final concentration of 100 M
Inhibitor
Ki (M) at pHa:
7.0 8.0 9.0 10.0
2,4-PDCA 17  1 35  1 160  10 520  50
2-Picolinic acid 46  2 76  1 440  40 1,100  80
a Values are means  standard deviations.
TABLE 5. pH dependence of the kinetic constants Km and kcat for
wild-type CphA by using the substrate imipenema
pH Km (M) kcat (s	1) kcat/Km (M	1 s	1)
7.0 120  10 210  8 1.8
8.0 83  6 140  4 1.7
9.0 63  3 49  1 0.78
10.0 ND ND 0.44
a Values are means  standard deviations. ND, not determined (see text).
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ion, acts as an NO-chelating ligand, and interacts with the
enzyme active site with both electrostatic and hydrophobic
contacts (Fig. 4). The zinc ion is coordinated to five ligands: a
triad of residues, Asp120-Cys221-His263, the 2,4-PDCA pyridyl
nitrogen (N-1), and one oxygen of the carboxylate group in
position 2 (O-22). The refined Zn-to-N-1 and Zn-to-O-22 dis-
tances are 2.2 and 2.3 Å, respectively. The zinc-bound 2-car-
boxylate group is in a position to form hydrogen bonds with the
side chain of Lys224 and the Asn233 backbone nitrogen and is
coplanar with the pyridine ring. In contrast, the 4-carboxylate
group is slightly out of plane [ (C-3–C-4–C-41–O-42)  23.6°]
(Fig. 5). The distance of 3.7 Å between Val67 CG2 and the
carboxylate oxygen (O-42) may explain the slight rotation.
In addition to the four strong electrostatic interactions de-
scribed above, three hydrophobic contacts contribute to the
stabilization of the inhibitor in the active site: (i) Asn233 CB
and C-3 (3.7 Å), (ii) Trp87 CH2 and C-5 and C-6 (3.7 Å for
both), and (iii) Val67 CG2 and C-41 (3.9 Å). (The carboxylic
acids’ carbon atoms are numbered 21 and 41.)
The positions of the groups on the 2,4-PDCA pyridine ring
may explain its specificity for CphA. The electron-withdrawing
effect of a second carboxylate group in position 4 may lower
the chelation strength but does not cause a decrease in Ki,
probably because of the hydrophobic interaction between the
carboxylate group and the Val67 residue. Additionally, the
4-carboxylate group points towards the solvent, interacting
with a network of water molecules (not shown). This may (i)
reduce the energy of desolvation required for the transfer of
2,4-PDCA from the aqueous buffer to the CphA-Zn(II) active
site and therefore contribute to the potency of the inhibitor
and (ii) participate in the overall stabilization of the CphA–
Zn(II)–2,4-PDCA complex by additional enzyme/ligand inter-
actions through hydrogen bonding via water molecules.
Finally, 2-picolinic acid and 2,4-PDCA have similar Ki values
(Table 3), 5.7 and 4.3 M, respectively. Both molecules bear
the same pyridyl nitrogen and C-2 carboxylate functions, which
may be involved in the same four strong electrostatic interac-
tions described above. Moreover, superimposition of 2,3-
PDCA and 2,5-PDCA with 2,4-PDCA in the CphA–Zn(II)–
2,4-PDCA complex structure shows that Asn233 and Trp87
hinder the binding of 2,3-PDCA and 2,5-PDCA, respectively,
consistent with their respective Ki values (420 and 200 M)
(Table 3). Based on the CphA–Zn(II)–2,4-PDCA complex
structure, derivatization of the 2-picolinic acid molecule at the
C-4 position to improve inhibition can be envisaged. MBLs of
subclasses B1 and B3 are able to undergo dynamic conforma-
tional changes upon substrate binding, i.e., in order to accom-
modate the hydrophobic side chain of penicillins or potent
inhibitors (8); therefore, derivatizations at the picolinic acid
C-5 and C-6 positions also cannot be ruled out.
The comparison of the CphA–Zn(II)–2,4-PDCA complex
structure with that of the reported CphA-Zn(II)-hydrolyzed
biapenem complex (Protein Data Bank code 1X8I) (18) re-
veals two interesting analogies: (i) a similar Gly232-Asn233
loop closure upon binding of 2,4-PDCA and hydrolyzed bia-
penem and (ii) analogous positions for the zinc-bound N-1 and
2-carboxylate group of 2,4-PDCA and for the zinc-bound N-4
and 3-carboxylate group of hydrolyzed biapenem.
Conclusion. Although the compounds analyzed in this study
do not give inhibition constants low enough for medicinal
studies, they may provide the basis for a new template for MBL
inhibition. Previous inhibition studies of MBLs have identified
many thiol-containing inhibitors that are generally less potent
FIG. 4. Active site of CphA-Zn(II) in complex with the pyridine-
2,4-dicarboxylate inhibitor (carbon atoms colored in orange). The con-
formational change upon inhibitor binding is represented by superim-
position of the wild-type Gly232 and Asn233 residues (green). The zinc
ion is represented as a blue sphere. This figure was prepared using the
program PYMOL.
FIG. 5. Difference electron density map (Fcomplex 	 Fwt) at con-
toured 2
 (orange) corresponding to the area of the complex structure
where the pyridine-2,4-dicarboxylate inhibitor was modeled. (Fcomplex
and Fwt are the structure factor amplitudes of the CphA crystal soaked
in solution containing 2,4-PDCA and of the uncomplexed crystals,
respectively.) The final refined coordinates of the inhibitor molecule,
zinc ion, and D120, C221, H263, and V67 side chains have been
superimposed. The distance between V67 (CG2) and 2,4-PDCA
(C-41) is indicated in angstroms.
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against subgroup B2 than against B1 and B3 (21, 34, 40). In this
study, a different chelating group has been found, forming part
of commercially available compounds. 2,4-PDCA is currently
being investigated as an inhibitor of Fe(II)-dependent oxy-
genases involved in collagen biosynthesis and transcriptional
regulation (10, 20, 38, 41). 2-Picolinic acid is the body’s natural
zinc chelator that helps zinc absorption (12, 13). It has already
been tested as a dietary supplement and is currently used in
salt form with chromium as a muscle enhancer (14, 37, 43). The
lower Ki values for these two compounds identified them as the
most potent inhibitors, and the reasons for their success rather
than for any of the other pyridine carboxylate compounds were
found by examining the crystal structure of the CphA–Zn(II)–
2,4-PDCA complex. The tightly packed active site also sug-
gested that interactions occurring here might not occur in the
more open and flexible B1 and B3 enzymes, explaining the
specificity for subclass B2. The inhibition of both the mono-
and dizinc forms of the N116H-N220G mutant by 2,4-PDCA
showed that, of the compounds tested in this study, this inhib-
itor is not only the most successful but also the most specific to
CphA. Therefore, derivatives of pyridine carboxylate com-
pounds, and in particular 2,4-PDCA, would seem to be useful
starting points for the development of more-complex, selective,
nontoxic inhibitors of the metallo--lactamases of subclass B2.
ACKNOWLEDGMENTS
This work was supported by the Belgian Federal Government (PAI
P5/33), grants from the FNRS (FRFC grant no. 2.4.524.03 and
2.4.511.06 and Loterie Nationale 9.4538.03), the European Research
Training Network (MEBEL contract HPTR-CT-2002-00264), and the
targeted program COBRA, financed by the European Commission
(grant no. LSHM-CT-2003-503335).
We thank AMURA for a CASE studentship to B.M.R.L.
REFERENCES
1. Ambler, R. P. 1980. The structure of -lactamases. Philos. Trans. R. Soc.
Lond. B 289:321–331.
2. Bebrone, C., C. Anne, K. De Vriendt, B. Devreese, G. M. Rossolini, J. van
Beeumen, J. M. Frere, and M. Galleni. 2005. Dramatic broadening of the
substrate profile of the Aeromonas hydrophila CphA metallo--lactamase by
site-directed mutagenesis. J. Biol. Chem. 280:28195–28202.
3. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig,
I. N. Shindyalov, and P. E. Bourne. 2000. The Protein Data Bank. Nucleic
Acids Res. 28:235–242.
4. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification
scheme for -lactamases and its correlation with molecular structure. Anti-
microb. Agents Chemother. 39:1211–1233.
5. Cantor, C. R., and P. R. Schimmel. 1980. Biophysical chemistry. Part III: the
behavior of biological macromolecules. W. H. Freeman and Company, New
York, NY.
6. Carfi, A., S. Pares, E. Duee, M. Galleni, C. Duez, J. M. Frere, and O.
Dideberg. 1995. The 3-D structure of a zinc metallo--lactamase from Ba-
cillus cereus reveals a new type of protein fold. EMBO J. 14:4914–4921.
7. Collaborative Computational Project. 1994. The CCP4 suite: programs for
protein crystallography. Acta Crystallogr. Sect. D 50:760–763.
8. Concha, N. O., C. A. Janson, P. Rowling, S. Pearson, C. A. Cheever, B. P.
Clarke, C. Lewis, M. Galleni, J. M. Frere, D. J. Payne, J. H. Bateson, and
S. S. Abdel-Meguid. 2000. Crystal structure of the IMP-1 metallo--lacta-
mase from Pseudomonas aeruginosa and its complex with a mercaptocar-
boxylate inhibitor: binding determinants of a potent, broad-spectrum inhib-
itor. Biochemistry 39:4288–4298.
9. Cornish-Bowden, A. 2001. Fundamentals of enzyme kinetics. Portland Press
Ltd., London, United Kingdom.
10. Derian, C. K., W. VanDusen, C. T. Przysiecki, P. N. Walsh, K. L. Bekner,
R. J. Kaufman, and P. A. Friedman. 1989. Inhibitors of 2-ketoglutarate-
dependent dioxygenases block aspartyl -hydroxylation of recombinant hu-
man factor IX in several mammalian expression systems. J. Biol. Chem.
264:6615–6618.
11. Docquier, J. D., J. Lamotte-Brasseur, M. Galleni, G. Amicosante, J. M.
Frere, and G. M. Rossolini. 2003. On functional and structural heterogeneity
of VIM-type metallo--lactamases. J. Antimicrob. Chemother. 51:257–266.
12. Evans, G. W., C. I. Grace, and H. J. Votava. 1975. A proposed mechanism of
zinc absorption in the rat. Am. J. Physiol. 228:501–505.
13. Evans, G. W., and P. E. Johnson. 1980. Characterization and quantitation of
a zinc-binding ligand in human milk. Pediatr. Res. 14:876–880.
14. Fox, G. N., and Z. Sabovic. 1998. Chromium picolinate supplementation for
diabetes mellitus. J. Fam. Pract. 46:83–86.
15. Franceschini, N., B. Caravelli, J.-D. Docquier, M. Galleni, J.-M. Fre`re, G.
Amicosante, and G. M. Rossolini. 2000. Purification and biochemical char-
acterization of the VIM-1 metallo--lactamase. Antimicrob. Agents Che-
mother. 44:3003–3007.
16. Frere, J. M. 1995. -Lactamases and bacterial resistance to antibiotics. Mol.
Microbiol. 16:385–395.
17. Galleni, M., J. Lamotte-Brasseur, G. M. Rossolini, J. Spencer, O. Dideberg,
and J.-M. Fre`re. 2001. Standard numbering scheme for class B -lactamases.
Antimicrob. Agents Chemother. 45:660–663.
18. Garau, G., C. Bebrone, C. Anne, M. Galleni, J. M. Frere, and O. Dideberg.
2005. A metallo--lactamase enzyme in action: crystal structures of the
monozinc carbapenemase CphA and its complex with biapenem. J. Mol.
Biol. 345:785–795.
19. Ghuysen, J. M. 1991. Serine -lactamases and penicillin-binding proteins.
Annu. Rev. Microbiol. 45:37–67.
20. Hanauske-Abel, H. M. 1991. Prolyl-4-hydroxylase, a target enzyme for drug
development. Design of suppressive agents and the in vitro effects of inhib-
itors and proinhibitors. J. Hepatol. 13(Suppl. 3):S8–S15.
21. Heinz, U., R. Bauer, S. Wommer, W. Meyer-Klaucke, C. Papamichaels, J.
Bateson, and H. W. Adolph. 2003. Coordination geometries of metal ions in
D- or L-captopril-inhibited metallo--lactamases. J. Biol. Chem. 278:20659–
20666.
22. Hernandez-Valladares, M., A. Felici, G. Weber, H. W. Adolph, M. Zeppezauer,
G. M. Rossolini, G. Amicsante, J. M. Frere, and M. Galleni. 1997. Zn(II)
dependence of the Aeromonas hydrophila AE036 metallo--lactamase activity
and stability. Biochemistry 36:11534–11541.
23. Hernandez-Valladares, M., M. Galleni, J. M. Frere, A. Felici, M. Perilli, N.
Franceschini, G. M. Rossolini, A. Oratore, and G. Amicosante. 1996. Over-
production and purification of the Aeromonas hydrophila CphA metallo--
lactamase expressed in Escherichia coli. Microb. Drug Resist. 2:253–256.
24. Hernandez-Valladares, M., M. Kiefer, U. Heinz, R. P. Soto, W.
Meyer-Klaucke, H. F. Nolting, M. Zeppezauer, M. Galleni, J. M. Frere,
G. M. Rossolini, G. Amicosante, and H. Adolph. 2000. Kinetic and spec-
troscopic characterization of native and metal-substituted -lactamase
from Aeromonas hydrophila AE036. FEBS Lett. 467:221–225.
25. Ivan, M., T. Haberberger, D. C. Gervasi, K. S. Michelson, V. Gunzler, K.
Kondo, H. F. Yang, I. Sorokina, R. C. Conaway, J. W. Conaway, and G.
Kaelin. 2002. Biochemical purification and pharmacological inhibition of a
mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc.
Natl. Acad. Sci. USA 99:13459–13464.
26. Jin, W., Y. Arakawa, H. Yasuzawa, T. Taki, R. Hashiguchi, K. Mitsutani, A.
Shoga, Y. Yamaguchi, H. Kurosaki, N. Shibata, M. Ohta, and M. Goto. 2004.
Comparative study of the inhibition of metallo--lactamases (IMP-1 and
VIM-2) by thiol compounds that contain a hydrophobic group. Biol. Pharm.
Bull. 27:851–856.
27. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved
methods for building protein models in electron density maps and the loca-
tion of errors in these models. Acta Crystallogr. Sect. A 47:110–119.
28. Kimura, S., Y. Ishii, and K. Yamaguchi. 2005. Evaluation of dipicolinic acid
for the detection of IMP- or VIM-type metallo--lactamase-producing
Pseudomonas aeruginosa clinical isolates. Diagn. Microbiol. Infect. Dis. 53:
241–244.
29. Kurosaki, H., Y. Yamaguchi, T. Higashi, K. Soga, S. Matsueda, H. Yumoto,
S. Misumi, Y. Yamagata, Y. Arakawa, and M. Goto. 2005. Irreversible inhi-
bition of metallo--lactamase (IMP-1) by 3-(3-mercaptopropionylsulfanyl)-
propionic acid pentafluorophenyl ester. Angew. Chem. Int. Ed. 44:3861–
3864.
30. Laraki, N., N. Franceschini, G. M. Rossolini, P. Santucci, C. Meunier, E. de
Pauw, G. Amicosante, J. M. Fre`re, and M. Galleni. 1999. Biochemical char-
acterization of the Pseudomonas aeruginosa 101/1477 metallo--lactamase
IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 43:
902–906.
31. Matagne, A., A. Dubus, M. Galleni, and J. M. Frere. 1999. The -lactamase
cycle: a tale of selective pressure and bacterial ingenuity. Nat. Prod. Rep.
16:1–19.
32. Mercuri, P. S. 2002. Ph.D thesis. Universite´ de Lie`ge, Lie`ge, Belgium.
33. Mercuri, P. S., F. Bouillenne, L. Boschi, J. Lamotte-Brasseur, G.
Amicosante, B. Devreese, J. van Beeumen, J.-M. Fre`re, G. M. Rossolini,
and M. Galleni. 2001. Biochemical characterization of the FEZ-1 metallo-
-lactamase of Legionella gormanii ATCC 33297T produced in Escherichia coli.
Antimicrob. Agents Chemother. 45:1254–1262.
34. Mollard, C., C. Moali, C. Papamicael, C. Damblon, S. Vessilier, G.
Amicosante, C. J. Schofield, M. Galleni, J. M. Frere, and G. C. Roberts.
2001. Thiomandelic acid, a broad spectrum inhibitor of zinc -lactamases:
kinetic and spectroscopic studies. J. Biol. Chem. 276:45015–45023.
35. Paul-Soto, R., R. Bauer, J. M. Frere, M. Galleni, W. Meyer-Klaucke, H.
VOL. 51, 2007 COMPETITIVE INHIBITORS OF THE CphA METALLO--LACTAMASE 2141
Nolting, G. M. Rossolini, D. de Seny, M. Hernandez-Valladares, M.
Zeppezauer, and H. W. Adolph. 1999. Mono- and binuclear Zn2--
lactamase. Role of the conserved cysteine in the catalytic mechanism.
J. Biol. Chem. 274:13242–13249.
36. Paul-Soto, R., M. Hernandez-Valladares, M. Galleni, R. Bauer, M.
Zeppezauer, J. M. Frere, and H. W. Adolph. 1998. Mono- and binuclear
Zn--lactamase from Bacteroides fragilis: catalytic and structural roles of
the zinc ions. FEBS Lett. 438:137–140.
37. Reading, S. A. 1996. Chromium picolinate. J. Fla. Med. Assoc. 83:29–31.
38. Sharir, M., and T. J. Zimmerman. 1993. In vitro inhibition of collagen
formation by 2,4-pyridine dicarboxylate and minoxidil in rabbit corneal
fibroblasts. Curr. Eye Res. 12:553–559.
39. Siemann, S., A. J. Clarke, T. Viswanatha, and G. I. Dmitrienko. 2002.
Thiols as classical and slow-binding inhibitors of IMP-1 and other binuclear
metallo--lactamases. Biochemistry 42:1673–1683.
40. Siemann, S., D. P. Evanoff, L. Marrone, A. J. Clarke, T. Viswanatha, and
G. I. Dmitrienko. 2002. N-arylsulfonyl hydrazones as inhibitors of IMP-1
metallo--lactamase. Antimicrob. Agents Chemother. 46:2450–2457.
41. Tschank, G., D. G. Brocks, K. Engelbart, J. Mohr, E. Baader, V. Gunzler,
and H. M. Hanauske-Abel. 1991. Inhibition of prolyl hydroxylation and
procollagen processing in chick-embryo calvaria by a derivative of pyridine-
2,4-dicarboxylate. Characterization of the diethyl ester as a proinhibitor.
Biochem. J. 275:469–476.
42. Ullah, J. H., T. R. Walsh, I. A. Taylor, D. C. Emery, C. S. Verma, S. J.
Gamblin, and J. Spencer. 1998. The crystal structure of the L1 metallo--
lactamase from Stenotrophomonas maltophilia at 1.7 Å resolution. J. Mol.
Biol. 284:125–136.
43. Vincent, J. B. 2003. The potential value and toxicity of chromium picolinate
as a nutritional supplement, weight loss agent and muscle development
agent. Sports Med. 33:213–230.
44. Zervosen, A., M. H. Valladares, B. Devreese, C. Prosperi-Meys, H. W.
Adolph, P. S. Mercuri, M. Vanhove, G. Amicosante, J. van Beeumen,
J. M. Frere, and M. Galleni. 2001. Inactivation of Aeromonas hydrophila
metallo--lactamase by cephamycins and moxalactam. Eur. J. Biochem.
268:3840–3850.
2142 HORSFALL ET AL. ANTIMICROB. AGENTS CHEMOTHER.
